The CEO of Sphere Fluidics (Dr Frank F. Craig) will be attending, and exhibiting at, a Spring Reception organised for the portfolio companies, investors and potential investors in the new University of Cambridge Enterprise Fund (UCEF). The latter fund is the only University SEIS/EIS Fund to co-invest in University spin-outs. The reception will be held in Cambridge (UK) on the 7th of March 2013. Dr Craig comments “The UCEF is an investor in Sphere Fluidics and we will be very pleased to participate in this exciting event and meet and talk with some of our investors”.
Sphere Fluidics, an early-stage, Cambridge-based company focusing on developing novel products and services for single cell analysis, has just completed a £1.6 million investment round. The investment syndicate was led by 24Haymarket and included the Royal Society, Cambridge Enterprise Limited, Providence Investment Company Limited, University of Cambridge Enterprise Fund, the London Business Angels Roundtable EIS Fund and a number of individual angels from London (including members of the London Business Angels) and Cambridge. Frank Craig, Sphere Fluidics’ CEO, comments, “We are very pleased to close this round as it gives us the resources to further develop our business. There was strong interest in the company and we were pleased to welcome 24Haymarket into an impressive syndicate of investors. I am excited about further applying our exciting technology to major Life Sciences markets and accelerating its commercialisation”.
Dr Frank F. Craig (CEO) and Dr Xin Liu (Senior Scientist) will be attending a Single Cell Analysis Europe” conference in Barcelona (Spain) on 5th-6th of March 2013. Sphere Fluidics will be both attending the technical talks and promoting its new services and products at the conference. Dr Craig says “This is an excellent conference with an impressive list of international attendees. It is also a sign that this area is now becoming of significant importance to the scientific community”. More conference information can be found here.